Exane Derivatives’s Unity U Stock Holding History

Exane Derivatives’s Portfolio U Stock Details U Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,624	Closed	-$360K	–	958
2022 Q1	$360K	Buy	+3,624	New	+$375K	0.1%	227
2021 Q4	–	Sell	-26	Closed	-$3.28K	–	1007
2021 Q3	$3.28K	Sell	26 -170	-87%	-$20.1K	﹤0.01%	763
2021 Q2	$20.3K	Hold	196	–	–	﹤0.01%	701
2021 Q1	$19.7K	Buy	+196	New	+$24.1K	0.01%	567

Other funds holding U

SLG

Silver Lake Group Menlo Park, California $4.58B AUM 24.86% 1-Year Est. Return

SUT

SC US (TTGP) Menlo Park, California $31.9B AUM 28.45% 1-Year Est. Return

Resolute Advisors San Francisco, California $417M AUM 60.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SXM

SC XII Management Menlo Park, California $194M AUM 17.69% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Exane Derivatives's U Position: Q2 2022 in Review

Exane Derivatives sold out of Unity (U) in Q2 2022, closing a stake of 3,624 shares — an estimated $360K sold.

Exane Derivatives first reported a position in U in Q1 2021 and held it in 4 quarters. The position peaked at $360K in Q1 2022. 489 funds tracked by Wall St. Rank hold U as of Q2 2022.

Exane Derivatives reported no remaining Unity position as of Q2 2022 after selling out during the quarter.
Exane Derivatives sold 3,624 Unity shares in Q2 2022, an estimated $360K.
Exane Derivatives first reported a position in Unity in Q1 2021 and held it in 4 quarters.
Exane Derivatives's Unity position peaked at $360K in Q1 2022.
489 funds tracked by Wall St. Rank held Unity as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.